Get the Stockscreener App
0.3328
2.09%
-0.0071
Pre-market:
.32
-0.0128
-3.85%
Oncolytics Biotech Inc stock is traded at $0.3328, with a volume of 652.70K.
It is down -2.09% in the last 24 hours and down -38.94% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.3399
Open:
$0.3505
24h Volume:
652.70K
Relative Volume:
1.37
Market Cap:
$29.56M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-1.2582
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-8.67%
1M Performance:
-38.94%
6M Performance:
-61.53%
1Y Performance:
-68.90%
1-Day Range:
$0.331
$0.3528
1-Week Range:
$0.3301
$0.38
52-Week Range:
$0.3301
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.3328 | 32.37M | 0 | -20.31M | -21.07M | -0.2645 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
(ONC) Technical Patterns and Signals (ONC:CA) - news.stocktradersdaily.com
(ONC) Market Dynamics and Trading Signals (ONC:CA) - news.stocktradersdaily.com
(ONC) Proactive Strategies (ONC:CA) - news.stocktradersdaily.com
Against the rise of early onset cancer: a Mugglehead roundup - Mugglehead Magazine
(ONC) Advanced Equity Analysis (ONC:CA) - news.stocktradersdaily.com
HC Wainwright Has Pessimistic Outlook of TSE:ONC Q2 Earnings - Defense World
Stocks In Play - Baystreet.ca
Q2 EPS Forecast for Oncolytics Biotech Reduced by Analyst - Defense World
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech Inc - MENAFN.com
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Stocks in play: Oncolytics Biotech® Inc. - The Globe and Mail
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca
Dow slumps 460 points, or 1.1%, in early trading following Trump's latest tariff threats targeting Europe and Apple - The Globe and Mail
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - marketscreener.com
Oncolytics Biotech Inc. to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics (ONCY) Unveils Promising Phase I/II Clinical Trial Da - GuruFocus
Oncolytics Biotech Unveils Promising Pelareorep Data at ASCO 2025 - TipRanks
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities | ONCY Stock News - GuruFocus
Oncolytics Brief: Presenting New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - Nasdaq
HC Wainwright Issues Negative Outlook for TSE:ONC Earnings - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
(ONC) Strategic Market Analysis (ONC:CA) - news.stocktradersdaily.com
ONCY: Analyst Reiterates Buy Rating with $5.00 Price Target | ONCY Stock News - GuruFocus
Analysts Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Price Target at $4.33 - Defense World
Oncolytic Virus Therapy Market Detailed In New Research Report - openPR.com
Jones Trading Reaffirms “Hold” Rating for Oncolytics Biotech (NASDAQ:ONCY) - Defense World
Options Volatility and Implied Earnings Moves Today, May 16, 2025 - The Globe and Mail
(ONC) Market Performance Analysis (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech (ONCY) Downgraded by Jones Trading | ONCY Sto - GuruFocus
Oncolytics (ONCY) Downgraded Amid CEO Search and Capital Concerns | ONCY Stock News - GuruFocus
Oncolytics Biotech (ONCY) Downgraded by Jones Trading | ONCY Stock News - GuruFocus
Oncolytics Biotech’s Earnings Call: Optimism Amid Challenges - TipRanks
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Oncolytics Biotech Reports Q1 Results and Clinical Progress - TipRanks
Oncolytics Biotech Reports Q1 2025 Financial Results - TipRanks
Oncolytics Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Oncolytics Biotech Reports Promising Q1 Results and Advances in Cancer Treatment - TipRanks
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum - marketscreener.com
How To Trade (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights - Kilgore News Herald
Oncolytics Biotech Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
(ONC) Trading Strategy and Analysis (ONC:CA) - news.stocktradersdaily.com
Off-market insider buying at Ansar Financial and Dev. (AFD) - The Globe and Mail
(ONC) Stock Analysis and Trading Signals (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech to Discuss Q1 2025 Financial Results on May 14 - TipRanks
Stocks In Play: Oncolytics Biotech® Inc. By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Inc. - Baystreet.ca
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):